Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype : effects on HDL quality, LDL susceptibility to oxidation and DNA damage

This study was conducted to examine a complex effect of ciprofibrate therapy in patients with atherogenic lipoprotein phenotype. Effects of ciprofibrate were studied on HDL subpopulations, HDL ability to esterify cholesterol (FER(HDL)), susceptibility of LDL to oxidation as well as on in vivo oxidat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 1998-11, Vol.54 (9-10), p.697-699
Hauptverfasser:	RASLOVA, K, DOBIASOVA, M, NAGYOVA, A, FABRY, R, RAUCHOVA, H, DUSINSKA, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Arteriosclerosis - genetics Biological and medical sciences Cholesterol Ciprofibrate Clofibric Acid - analogs & derivatives Clofibric Acid - therapeutic use Comet assay Cytotoxicity Deoxyribonucleic acid DNA DNA Damage Female Fibric Acids General and cellular metabolism. Vitamins Genotype & phenotype Humans Hypolipidemic Agents - therapeutic use Kinetics Lipid metabolism Lipoproteins Lipoproteins (high density) Lipoproteins (low density) Lipoproteins - genetics Lipoproteins, HDL - blood Lipoproteins, HDL - genetics Lipoproteins, LDL - blood Lipoproteins, LDL - genetics Lymphocytes Lymphocytes - drug effects Lymphocytes - metabolism Male Medical sciences Middle Aged Oxidation Oxidation-Reduction Pharmacology. Drug treatments Phenotype Triglycerides
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!